Safety and efficacy of galantamine (Reminyl) in severe Alzheimer's disease (the SERAD study): a rand...
Safety and efficacy of galantamine (Reminyl) in severe Alzheimer's disease (the SERAD study): a randomised, placebo-controlled, double-blind trial
About this item
Full title
Author / Creator
Burns, Alistair, MD , Bernabei, Roberto, MD , Bullock, Roger, MD , Jentoft, Alfonso J Cruz, MD , Frölich, Lutz, MD , Hock, Christoph, MD , Raivio, Minna, MD , Triau, Eric, MD , Vandewoude, Maurits, MD , Wimo, Anders, MD , Came, Elizabeth, PhD , Van Baelen, Bart, MSc , Hammond, Gerry L, BSc , van Oene, Joop C, PhD and Schwalen, Susanne, MD
Publisher
England: Elsevier Ltd
Journal title
Language
English
Formats
Publication information
Publisher
England: Elsevier Ltd
Subjects
More information
Scope and Contents
Contents
Summary Background The efficacy of galantamine has been shown in patients with mild, moderate, and advanced moderate Alzheimer's disease (AD). Here we report its efficacy in patients with severe AD. Methods Between December, 2003, and March, 2007, patients aged 84 (SD 6) years with severe AD (mini-mental state examination [MMSE] score 5–12 points),...
Alternative Titles
Full title
Safety and efficacy of galantamine (Reminyl) in severe Alzheimer's disease (the SERAD study): a randomised, placebo-controlled, double-blind trial
Authors, Artists and Contributors
Author / Creator
Bernabei, Roberto, MD
Bullock, Roger, MD
Jentoft, Alfonso J Cruz, MD
Frölich, Lutz, MD
Hock, Christoph, MD
Raivio, Minna, MD
Triau, Eric, MD
Vandewoude, Maurits, MD
Wimo, Anders, MD
Came, Elizabeth, PhD
Van Baelen, Bart, MSc
Hammond, Gerry L, BSc
van Oene, Joop C, PhD
Schwalen, Susanne, MD
Identifiers
Primary Identifiers
Record Identifier
TN_cdi_proquest_journals_201488767
Permalink
https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_proquest_journals_201488767
Other Identifiers
ISSN
1474-4422
E-ISSN
1474-4465
DOI
10.1016/S1474-4422(08)70261-8
